Consolidated Statement Of Cash Flows

Modalis Therapeutics Corporation - Filing #7571290

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-2,585,442,000 JPY
-2,707,031,000 JPY
-791,714,000 JPY
-745,417,000 JPY
Depreciation
123,675,000 JPY
77,870,000 JPY
Impairment losses
996,800,000 JPY
JPY
Interest and dividend income
-57,000 JPY
-57,000 JPY
Interest expenses
4,823,000 JPY
1,090,000 JPY
Foreign exchange losses (gains)
-52,521,000 JPY
-11,729,000 JPY
Subtotal
-1,888,492,000 JPY
-1,232,400,000 JPY
Income taxes paid
-1,210,000 JPY
-1,210,000 JPY
Net cash provided by (used in) operating activities
-1,895,773,000 JPY
-747,466,000 JPY
Other, net
-15,722,000 JPY
-112,179,000 JPY
Interest and dividends received
57,000 JPY
57,000 JPY
Interest paid
-6,128,000 JPY
JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-197,287,000 JPY
-107,111,000 JPY
Net cash provided by (used in) investing activities
-185,719,000 JPY
171,563,000 JPY
Other, net
JPY
332,000 JPY
Cash flows from financing activities
Purchase of treasury shares
JPY
-97,000 JPY
Net cash provided by (used in) financing activities
63,683,000 JPY
72,633,000 JPY
Other, net
-910,000 JPY
JPY
Effect of exchange rate change on cash and cash equivalents
14,778,000 JPY
17,987,000 JPY
Net increase (decrease) in cash and cash equivalents
-2,003,031,000 JPY
-485,282,000 JPY
Cash and cash equivalents
2,933,162,000 JPY
4,936,193,000 JPY
5,421,476,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.